Clinical Trial Update: Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating abatacept in combination with ixazomib citrate and dexamethasone in relapsed/refractory multiple myeloma was terminated, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Multiple Myeloma

Drugs mentioned

• Abatacept (abatacept)
• DEXAMETHASONE (Dexamethasone)
• Ixazomib citrate (Ixazomib)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2024-05-16